Cariprazine vs Brexpiprazole

How they're similar

Cariprazine and brexpiprazole both act as partial agonists at the D2 dopamine receptor. That means they don't fully block dopamine or fully stimulate it. They sit in between, which is the mechanism behind the whole third-generation class. Both also act at 5HT1A as partial agonists and at 5HT2A as antagonists, a serotonin profile shared with aripiprazole. That shared profile is part of why all three drugs have a lower risk of some traditional antipsychotic side effects, especially prolactin elevation and, to a degree, weight gain.

Both are used in schizophrenia and both carry the class boxed warning about increased mortality when antipsychotics are given to older adults with dementia-related psychosis. Both can cause akathisia, that inner restlessness where sitting still feels almost impossible, though they cause it at different rates and at different points in treatment. Both can cause some weight gain, some sedation, and some GI upset, especially early on. Neither is considered high-metabolic-burden the way olanzapine or quetiapine are, but neither is fully weight-neutral either.

Both are once-daily oral medications. Both come only as brand-name products in the United States and are expensive without insurance. Both are used off-label for a range of conditions beyond their approved uses, which is common with newer antipsychotics.

How they differ

The receptor profile is where things start to split. Cariprazine has a much higher affinity for D3 than for D2, which is unique among antipsychotics on the U.S. market. D3 receptors are concentrated in brain regions tied to motivation, reward, and mood, and there is a working theory that D3 preference is part of why cariprazine performs well in bipolar depression and in negative symptoms of schizophrenia. It's a theory, not a proven cause, and the honest answer is we don't fully know how much of the clinical difference comes from D3 specifically. Brexpiprazole doesn't share that D3 preference. It does add antagonism at alpha-1B and alpha-2C adrenergic receptors, which may contribute to its sedation and its usefulness in agitation.

The half-lives are also very different. Brexpiprazole has a half-life around 91 hours, which is long, and it takes about 10 to 12 days to reach steady state. Cariprazine goes further. Its parent drug has a half-life of 48 to 96 hours, but it also has an active metabolite (didesmethyl-cariprazine) with a half-life that can stretch to 1 to 3 weeks. Full steady state takes weeks, and side effects can linger for weeks after stopping. That's a real practical difference. If someone starts cariprazine and has trouble, the response to lowering or stopping the dose is slow.

The approved uses tell part of the story too. Cariprazine is one of very few medications with monotherapy approval for bipolar I depression, and it's approved for both mania and depression sides of bipolar, plus MDD as an add-on. Brexpiprazole doesn't have a bipolar indication. It's approved for schizophrenia, MDD adjunct, and, as of 2023, agitation in Alzheimer's disease. That AD agitation approval was a first for the class, and it changed how some clinicians think about this drug in older adults. It doesn't mean brexpiprazole is safe in that population without care. The boxed warning about mortality in dementia still applies. It means there is finally a drug with real trial data for that specific use.

Side effect tendencies

Akathisia is the side effect that comes up most often with both drugs, and the rates aren't the same. Cariprazine causes akathisia more often, especially in the first several weeks of treatment. The rate in trials is around 15 to 20 percent, higher at higher doses. It can be uncomfortable enough that people stop the drug. Brexpiprazole causes akathisia less often, and it's often cited as a reason to try brexpiprazole in someone who couldn't tolerate aripiprazole. The rate is more in the 5 to 10 percent range, still real but less common.

Weight gain sits somewhere in the middle for both. Neither is in the same category as olanzapine, but both can add a few pounds over months, more for some people than others. Metabolic effects on glucose and lipids exist but are modest. Sedation is possible with both, sometimes more with brexpiprazole because of the alpha-1B activity. Cariprazine can cause insomnia in some people and sedation in others, which is not unusual for partial agonists.

Because cariprazine's active metabolite hangs around for weeks, side effects can persist after the last dose. If akathisia shows up two weeks in, lowering the dose or stopping doesn't bring immediate relief. That slow tail is worth naming up front with anyone starting the drug. Brexpiprazole clears faster, but still takes a couple of weeks to fully leave the system.

Both drugs can cause the more serious antipsychotic side effects, though at lower rates than older agents. Tardive dyskinesia is a risk with any dopamine blocker, and the third-generation class isn't immune. Neuroleptic malignant syndrome is rare but possible. Both can lower the seizure threshold slightly. Prolactin elevation is uncommon with either, unlike risperidone or paliperidone.

What tips the choice

The diagnosis often decides it. For bipolar depression as a stand-alone target, cariprazine has the approval and the trial data. Brexpiprazole isn't studied in bipolar and isn't a natural pick there. For agitation in Alzheimer's disease, brexpiprazole now has the only approval in class, though the risk-benefit conversation with families still needs to be careful given the mortality warning. For schizophrenia, either works, and the choice usually comes down to side effect fit.

For someone who tried aripiprazole and got severe akathisia, brexpiprazole is a reasonable next step. The receptor profile is similar but the tolerability tends to be gentler, and many people who couldn't stay on aripiprazole do fine on brexpiprazole. For someone who needs the D3 preference, or someone with prominent negative symptoms of schizophrenia, cariprazine has the mechanistic case, though the clinical difference isn't always dramatic in real life.

Half-life matters too. If a person is likely to miss doses occasionally, the very long half-life of cariprazine forgives a missed dose better than most drugs. If a person needs the flexibility to stop quickly because of another medical issue, the slow tail is a drawback. Insurance and cost also matter. Both are brand-only and expensive, and formulary preferences vary widely.

Prior response is worth weighing. If a person did well on aripiprazole in the past, brexpiprazole is often a natural cousin to try. If a person had a partial response to another antipsychotic and needs a different receptor angle, cariprazine's D3 activity is one of the few genuinely different options.

Common questions

Why does cariprazine take so long to reach steady state? Because of its active metabolite. The parent drug clears in a few days, but the metabolite has a half-life that can stretch to three weeks. Steady state is when the amount going in each day matches the amount clearing, and with a metabolite that long, it takes weeks to get there. It also means side effects can appear later than expected, and they can persist for weeks after stopping.

Is brexpiprazole safer than aripiprazole? It's often better tolerated for akathisia and activation, which are the main reasons people stop aripiprazole. Otherwise the safety profiles are similar. The two drugs share the same boxed warnings and the same general side effect list. Brexpiprazole isn't safer in a global sense. It's just easier to sit with for many people.

Can either be used for depression on its own? Cariprazine has monotherapy approval for bipolar I depression, so yes in that context. Neither is approved as monotherapy for unipolar major depression. Both are approved as add-ons to an antidepressant when the antidepressant alone isn't enough, which is a common use of the third-generation class in outpatient psychiatry.

How long before I know if it's working? For acute effects on psychosis or mania, the first two to three weeks are informative. For depression targets, it can take four to six weeks or more, and cariprazine specifically may keep improving for longer given its long tail to steady state. Neither drug is fast in the way benzodiazepines or some sleep meds are.

Do these cause tardive dyskinesia? Any drug that acts at D2 can, and the risk grows with time on the medication. The third-generation class appears to carry a lower risk than older agents like haloperidol, but the risk isn't zero. Anyone taking either drug long-term should be checked periodically for early involuntary movements, usually with a brief exam called the AIMS.

Sources

This guide draws on current prescribing information and public health references. It is reviewed for clinical accuracy and updated as guidance changes.

1. U.S. Food and Drug Administration. Cariprazine (Vraylar) prescribing information.
2. U.S. Food and Drug Administration. Brexpiprazole (Rexulti) prescribing information.
3. MedlinePlus, U.S. National Library of Medicine.
4. National Institute of Mental Health. Mental health medications.